Vera Therapeutics Reports $80.3 Million Net Loss in Q3 2025, Increases R&D Spending

Vera Therapeutics, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $80.3 million, compared to a net loss of $46.6 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $208.5 million, up from $108.7 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged by 40% to $56.5 million in the third quarter, driven by costs associated with clinical trials and increased personnel expenses. General and administrative expenses also rose significantly, reaching $27.5 million for the quarter, a 189% increase from the previous year, primarily due to higher employee compensation and costs related to commercialization planning for the company's lead product candidate, atacicept.

In terms of liquidity, Vera Therapeutics reported cash, cash equivalents, and marketable securities totaling $497.4 million as of September 30, 2025, a decrease from $640.9 million at the end of 2024. The company utilized $171.1 million in cash for operating activities during the first nine months of 2025, compared to $95.5 million in the same period of 2024. The increase in cash used for operations reflects the company's ongoing investment in its clinical development programs. The company anticipates continued net losses and cash outflows as it advances its product candidates, including atacicept, MAU868, and VT-109.

Strategically, Vera Therapeutics has made notable advancements in its clinical pipeline. The company completed full enrollment in the pivotal Phase 3 trial of atacicept for immunoglobulin A nephropathy (IgAN) and reported positive primary endpoint results from earlier trials. Additionally, the company acquired worldwide development and commercial rights to VT-109, a novel dual BAFF/APRIL inhibitor, in January 2025. These developments are expected to enhance the company's product offerings and market potential.

Operationally, Vera Therapeutics has increased its employee headcount to support its expanding research and development efforts. The company is focused on scaling up its external manufacturing capacity and establishing a sales and marketing infrastructure in anticipation of potential product approvals. As of September 30, 2025, the company had 63.9 million shares of Class A common stock outstanding, reflecting ongoing equity activities to support its capital needs.

Looking ahead, Vera Therapeutics expects to continue incurring significant losses as it progresses through clinical trials and prepares for potential commercialization of its product candidates. The company plans to raise additional capital through equity or debt financing to support its operations and development activities. Management believes that its current cash position will be sufficient to fund operations for at least the next 12 months, but acknowledges the need for further funding to achieve its long-term business objectives.